芳香化酶抑制剂在乳腺癌中的临床应用
Clinical utilities of aromatase inhibitors in breast cancer.
作者信息
Chumsri Saranya
机构信息
Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
出版信息
Int J Womens Health. 2015 May 6;7:493-9. doi: 10.2147/IJWH.S69907. eCollection 2015.
Abstract
Aromatase is an enzyme that converts testosterones to estrogens. Inhibition of this enzyme has been shown to have several clinical utilities in breast cancer. Currently, there are three aromatase inhibitors (AIs) in clinical use, namely anastrozole, letrozole, and exemestane. AIs have been used in various clinical settings for breast cancer, ranging from chemoprevention in breast cancer to treating breast cancer in both early stage in the adjuvant setting and metastatic disease. This article reviews mechanism of action, AI classification, and clinical utilities of AIs in various clinical settings in the context of breast cancer.
摘要
芳香化酶是一种将睾酮转化为雌激素的酶。已证明抑制该酶在乳腺癌中有多种临床应用。目前，有三种芳香化酶抑制剂（AIs）正在临床使用，即阿那曲唑、来曲唑和依西美坦。AIs已被用于乳腺癌的各种临床场景，从乳腺癌的化学预防到辅助治疗早期乳腺癌以及转移性疾病。本文在乳腺癌的背景下综述了AIs在各种临床场景中的作用机制、AI分类及临床应用。
相似文献
1
Clinical utilities of aromatase inhibitors in breast cancer.芳香化酶抑制剂在乳腺癌中的临床应用
Int J Womens Health. 2015 May 6;7:493-9. doi: 10.2147/IJWH.S69907. eCollection 2015.
2
Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.所有芳香化酶抑制剂都一样吗？乳腺癌对照临床试验综述。
Clin Ther. 2005 Nov;27(11):1671-84. doi: 10.1016/j.clinthera.2005.11.013.
3
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.芳香化酶抑制剂用于治疗绝经后妇女的晚期乳腺癌。
Cochrane Database Syst Rev. 2007 Jan 24(1):CD003370. doi: 10.1002/14651858.CD003370.pub2.
4
Hormonal therapies for early breast cancer: systematic review and economic evaluation.早期乳腺癌的激素疗法：系统评价与经济学评估
Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. doi: 10.3310/hta11260.
5
Challenges in the endocrine management of breast cancer.乳腺癌内分泌治疗中的挑战。
Breast. 2003 Aug;12 Suppl 2:S2-19. doi: 10.1016/s0960-9776(03)80158-3.
6
The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.绝经后女性激素受体阳性乳腺癌的乳腺癌连续体：聚焦芳香化酶抑制剂的不断演变的管理选择
Ann Oncol. 2008 Jan;19(1):16-27. doi: 10.1093/annonc/mdm282. Epub 2007 Aug 9.
7
Emerging role of aromatase inhibitors in the adjuvant setting.芳香化酶抑制剂在辅助治疗中的新作用。
Am J Clin Oncol. 2003 Aug;26(4):S27-33. doi: 10.1097/00000421-200308001-00005.
8
Cardiovascular safety profiles of aromatase inhibitors : a comparative review.芳香化酶抑制剂的心血管安全性概况：一项比较性综述。
Drug Saf. 2006;29(9):785-801. doi: 10.2165/00002018-200629090-00003.
9
Use of aromatase inhibitors in breast carcinoma.芳香化酶抑制剂在乳腺癌中的应用。
Endocr Relat Cancer. 1999 Mar;6(1):75-92. doi: 10.1677/erc.0.0060075.
10
Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer.早期乳腺癌中芳香化酶抑制剂治疗的临床和经济效益。
Am J Health Syst Pharm. 2011 Sep 15;68(18):1699-706. doi: 10.2146/ajhp100492.
引用本文的文献
1
Intravascular Lipoleiomyoma With Expansion Into the Right Atrium and Subsequent Debulking Surgery.血管内平滑肌瘤扩展至右心房并随后进行减瘤手术
JACC Case Rep. 2025 Jun 18;30(15):103764. doi: 10.1016/j.jaccas.2025.103764.
2
Navigating the Intricacies of Tumor Heterogeneity: An Insight into Potential Prognostic Breast Cancer Biomarkers.探索肿瘤异质性的复杂性：深入了解潜在的乳腺癌预后生物标志物
Biomark Insights. 2024 Jun 17;19:11772719241256798. doi: 10.1177/11772719241256798. eCollection 2024.
3
Synthesis, and anticancer evaluation of novel pyridin-2-yl estra-1,3,5(10)-triene derivatives.新型吡啶-2-基雌甾-1,3,5(10)-三烯衍生物的合成与抗癌活性评价。
Future Med Chem. 2024;16(11):1127-1145. doi: 10.4155/fmc-2024-0039. Epub 2024 Apr 17.
4
The Use of Bone Density Scan in Monitoring Treatment Response in Patients Diagnosed with Osteoporosis: A Retrospective Cohort Study.骨密度扫描在监测骨质疏松症患者治疗反应中的应用：一项回顾性队列研究。
Int J Rheumatol. 2023 Oct 23;2023:2160346. doi: 10.1155/2023/2160346. eCollection 2023.
5
Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer.定制潜在天然化合物用于治疗管腔型乳腺癌。
Pharmaceuticals (Basel). 2023 Oct 16;16(10):1466. doi: 10.3390/ph16101466.
6
Novel 2-alkythio-4-chloro--[imino(heteroaryl)methyl]benzenesulfonamide Derivatives: Synthesis, Molecular Structure, Anticancer Activity and Metabolic Stability.新型 2-硫代-4-氯--[亚氨基(杂芳基)甲基]苯磺酰胺衍生物的合成、分子结构、抗癌活性和代谢稳定性。
Int J Mol Sci. 2023 Jun 5;24(11):9768. doi: 10.3390/ijms24119768.
7
Targeting Breast Cancer: An Overlook on Current Strategies.靶向乳腺癌：当前策略概述
Int J Mol Sci. 2023 Feb 11;24(4):3643. doi: 10.3390/ijms24043643.
8
Art of prevention: The importance of dermatologic care when using aromatase inhibitors.预防的艺术：使用芳香化酶抑制剂时皮肤护理的重要性。
Int J Womens Dermatol. 2021 Jul 17;7(5Part B):769-773. doi: 10.1016/j.ijwd.2021.07.002. eCollection 2021 Dec.
9
Hesperidin and its aglycone hesperetin in breast cancer therapy: A review of recent developments and future prospects.橙皮苷及其苷元橙皮素在乳腺癌治疗中的应用：近期进展与未来展望综述
Saudi J Biol Sci. 2021 Dec;28(12):6730-6747. doi: 10.1016/j.sjbs.2021.07.046. Epub 2021 Jul 21.
10
Blocking Estrogen Synthesis Leads to Different Hormonal Responses in Canine and Human Triple Negative Inflammatory Breast Cancer.阻断雌激素合成导致犬类和人类三阴性炎性乳腺癌出现不同的激素反应。
Cancers (Basel). 2021 Oct 2;13(19):4967. doi: 10.3390/cancers13194967.
本文引用的文献
1
Perfecting breast-cancer treatment--incremental gains and musculoskeletal pains.完善乳腺癌治疗——渐进式进展与肌肉骨骼疼痛
N Engl J Med. 2015 Jan 29;372(5):477-8. doi: 10.1056/NEJMe1413164. Epub 2014 Dec 11.
2
Adjuvant ovarian suppression in premenopausal breast cancer.绝经前乳腺癌的辅助性卵巢抑制
N Engl J Med. 2015 Jan 29;372(5):436-46. doi: 10.1056/NEJMoa1412379. Epub 2014 Dec 11.
3
Hormone therapy in premenopausal women with early-stage breast cancer.绝经前早期乳腺癌女性的激素治疗
N Engl J Med. 2014 Jul 10;371(2):175-6. doi: 10.1056/NEJMe1405746.
4
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.绝经前乳腺癌的辅助依西美坦加卵巢抑制。
N Engl J Med. 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1.
5
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.阿那曲唑预防绝经后高危女性乳腺癌（IBIS-II）：一项国际、双盲、随机、安慰剂对照试验。
Lancet. 2014 Mar 22;383(9922):1041-8. doi: 10.1016/S0140-6736(13)62292-8. Epub 2013 Dec 12.
6
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.氟维司群联合阿那曲唑或安慰剂对比依西美坦单药治疗用于绝经后激素受体阳性局部晚期或转移性乳腺癌患者在非甾体芳香化酶抑制剂进展后的 SOFEA 研究：一项综合的、多中心、III 期随机试验。
Lancet Oncol. 2013 Sep;14(10):989-98. doi: 10.1016/S1470-2045(13)70322-X. Epub 2013 Jul 29.
7
Aromatase inhibitor-induced arthralgia: a review.芳香酶抑制剂相关性关节痛：综述。
Ann Oncol. 2013 Jun;24(6):1443-9. doi: 10.1093/annonc/mdt037. Epub 2013 Mar 6.
8
Combination anastrozole and fulvestrant in metastatic breast cancer.阿那曲唑与氟维司群联合治疗转移性乳腺癌。
N Engl J Med. 2012 Aug 2;367(5):435-44. doi: 10.1056/NEJMoa1201622.
9
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.2010 年他莫昔芬和雷洛昔芬用于乳腺癌化学预防。
Breast Cancer Res Treat. 2012 Jul;134(2):875-80. doi: 10.1007/s10549-012-2089-2. Epub 2012 May 24.
10
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.事实：一项氟维司群和阿那曲唑联合与阿那曲唑单药作为受体阳性绝经后乳腺癌一线治疗的开放性随机 III 期研究。
J Clin Oncol. 2012 Jun 1;30(16):1919-25. doi: 10.1200/JCO.2011.38.1095. Epub 2012 Feb 27.
Zotero 插件